https://botanixpharma.com/wp-content/uploads/EP-analyst-Note.pdfG...

https://botanixpharma.com/wp-content/uploads/EP-analyst-Note.pdf

Gotta love this detailed, analytical coverage, substantiated by accurate research!

From that analyst note I particularly liked the clarity (for those new on these forums questioning price) - Sofdra is expected to be reimbursed at about $750 per prescription, with a 30% gross-to-net adjustment. The analyst later points out - Botanix has already engaged in discussions with payers to provide patients with frictionless access to Sofdra. Patients pay a portionof insurance premiums to their employer who then pay a managed care organization (MCO). The MCO covers part of the pharmacybenefit the patient receives. The patient then gets fulfillment at a pharmacy with a copay of $0 for covered claims, and a nominal amountfor those claims not covered

And the reaffirming of their sales/delivery model:
Botanix has developed an innovative sales model leveraging their dermatology drug launch experience to ensure easy patient access and
consistent refills. They use Lombard Pharmacy, a centralised pharmacy, to handle prescriptions and telehealth consults, reducing
administrative burdens, streamlining patients experience to eliminate barriers to refills and minimising script abandonment rate.
Botanix will employ ~25 sales representatives to target dermatology clinics, supported by key opinion leaders and patient advocates.
Their strategy includes telemedicine and an AI-enabled marketing campaign to reach potential patients efficiently. Manufacturing
is outsourced to contract development and manufacturing organisations, ensuring flexibility with no capital expenditures. Financial
obligations are minimal, with only a 5% royalty to Bodor Laboratories, making Botanix's model both innovative and effective in
mitigating risks.

And marketshare:
If FDA-approved, Sofdra will enter the market positioned between topical OTC antiperspirants and current medical treatments for hyperhidrosis. This positioning allows it to capture market share from both segments. There are ~3.7 M patients seeking treatment for PAH already within the clinical system. Through their sales teams, BOT aims to convert both new and existing patients by promoting Sofdra as an easier, better tolerated and more accessible option compared to alternatives like Botox or miraDry. Likewise, the consumer market for antiperspirants, estimated at $5-8 billion in the US (with ~US$0.6 B relevant to hyperhidrosis), offers another sizeable growth opportunity. BOT's strategy also includes leveraging a centralized pharmacy for streamlined access, engaging patients through telehealth, and deploying an AIdriven marketing campaign to activate and mobilise a further 6.3 M hyperhidrosis sufferers who are yet to seek out treatment. With the goal of achieving zero out-of-pocket costs for covered patients, combined with a favourable user experience, Sofdra is positioned to attract and retain patients...